Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 7/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 7/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 5/20 | 0.46 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 3/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25736014 | 0.74 | DUSP3 (0.56) | AKR1C2AKR1C1DUSP3 | |
| SCHEMBL410752 | 0.69 | RXRA (0.69) | AKR1C2AKR1C1DUSP3TTRRXRA | |
| SCHEMBL25711796 | 0.68 | DUSP3 (0.74) | AKR1C2AKR1C1DUSP3PTPN1 | |
| SCHEMBL3564211 | 0.64 | TTR (0.70) | AKR1C2AKR1C1DUSP3TTRACLY | |
| SCHEMBL11228183 | 0.61 | AKR1C2 (1.00) | AKR1C2AKR1C1PTPN1 | |
| SCHEMBL12322465 | 0.61 | RXRA (0.59) | AKR1C2AKR1C1TTRRXRARXRB | |
| SCHEMBL410759 | 0.60 | RXRA (0.66) | AKR1C2AKR1C1TTRRXRARXRB | |
| SCHEMBL463718 | 0.59 | TTR (1.00) | AKR1C2AKR1C1TTR | |
| SCHEMBL17364434 | 0.58 | AKR1C2 (0.61) | AKR1C2AKR1C1 | |
| SCHEMBL23296152 | 0.58 | RXRA (0.60) | AKR1C2AKR1C1RXRARXRBDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | AKR1C2 1230/4885AKR1C1 1327/4885DUSP3 74/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | AKR1C2 2154/4885AKR1C1 2279/4885DUSP3 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.